Hanan M.A. El Henafy , Mansour Abdullah Alghamdi , Hind Zafrah , Norah Saeed Al-Zahrani , Eman Mohamad El Nasha
{"title":"Impact of gold nanoparticle exposure on the development pancreas and kidney: Dose-dependent;oxidative stress; miRNA expression and Nrf2/ARE Signalling","authors":"Hanan M.A. El Henafy , Mansour Abdullah Alghamdi , Hind Zafrah , Norah Saeed Al-Zahrani , Eman Mohamad El Nasha","doi":"10.1016/j.intimp.2025.114409","DOIUrl":null,"url":null,"abstract":"<div><div>Background: The widespread use of gold nanoparticles (AuNPs) in consumer and medical products necessitates investigation into their potential developmental toxicity. Aim of the work: This study investigated the systemic effects of in-utero AuNP exposure on developing male rat offspring, focusing on metabolic, organ-specific, and cellular pathways. Materials and methods: Pregnant rats were intravenously administered AuNPs (5, 10, 15, or 20 mg/kg) or saline from gestational day 1 to birth. Male offspring were assessed at postnatal day 60 through biochemical and genetic analyses in the pancreas, kidney tissues, plasma analysis, and pancreatic histology.</div><div>Results: No mortality or clinical abnormalities occurred. However, in-utero AuNP high-dose exposure induced pancreatic abnormalities, including reduced endocrine function and morphological damage. Higher doses disrupt body and organ growth, leading to metabolic dysregulation (elevated glucose, amylase, lipase, reduced insulin), impairing glucose homeostasis, and pancreatic dysfunction. Compromised kidney function (elevated urea, creatinine, BUN, electrolyte imbalances), increased oxidative stress, and dysregulated inflammatory responses (altered TNF-α, IL-6, IL-10, Nrf2, NF-κB) were also observed. AuNPs induced apoptosis (increased caspase-3, decreased Bcl-2, and altered COX-2), as well as dysregulation of mRNA and miRNA expression. Affected genes included those related to stress and inflammation (p-p38, NOX4, iNOS, NF-κB, Akt, mTOR, Anxa3) and cellular survival signalling (miR-21, miR-382, miR-34a, miR-223). Pancreatic histopathology revealed dose-dependent tissue damage. Conclusion: These results indicate that AuNPs, especially at higher doses, disrupt multiple biological processes, inducing metabolic, renal, and pancreatic dysfunction via oxidative stress, inflammation, and cellular dysregulation. Further mechanistic research is crucial to establish safe applications, highlighting the need for biosafety assessments guided by green toxicology principles.</div></div>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":"152 ","pages":"Article 114409"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1567576925003996","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The widespread use of gold nanoparticles (AuNPs) in consumer and medical products necessitates investigation into their potential developmental toxicity. Aim of the work: This study investigated the systemic effects of in-utero AuNP exposure on developing male rat offspring, focusing on metabolic, organ-specific, and cellular pathways. Materials and methods: Pregnant rats were intravenously administered AuNPs (5, 10, 15, or 20 mg/kg) or saline from gestational day 1 to birth. Male offspring were assessed at postnatal day 60 through biochemical and genetic analyses in the pancreas, kidney tissues, plasma analysis, and pancreatic histology.
Results: No mortality or clinical abnormalities occurred. However, in-utero AuNP high-dose exposure induced pancreatic abnormalities, including reduced endocrine function and morphological damage. Higher doses disrupt body and organ growth, leading to metabolic dysregulation (elevated glucose, amylase, lipase, reduced insulin), impairing glucose homeostasis, and pancreatic dysfunction. Compromised kidney function (elevated urea, creatinine, BUN, electrolyte imbalances), increased oxidative stress, and dysregulated inflammatory responses (altered TNF-α, IL-6, IL-10, Nrf2, NF-κB) were also observed. AuNPs induced apoptosis (increased caspase-3, decreased Bcl-2, and altered COX-2), as well as dysregulation of mRNA and miRNA expression. Affected genes included those related to stress and inflammation (p-p38, NOX4, iNOS, NF-κB, Akt, mTOR, Anxa3) and cellular survival signalling (miR-21, miR-382, miR-34a, miR-223). Pancreatic histopathology revealed dose-dependent tissue damage. Conclusion: These results indicate that AuNPs, especially at higher doses, disrupt multiple biological processes, inducing metabolic, renal, and pancreatic dysfunction via oxidative stress, inflammation, and cellular dysregulation. Further mechanistic research is crucial to establish safe applications, highlighting the need for biosafety assessments guided by green toxicology principles.
期刊介绍:
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.
The subject material appropriate for submission includes:
• Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders.
• Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state.
• Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses.
• Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action.
• Agents that activate genes or modify transcription and translation within the immune response.
• Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active.
• Production, function and regulation of cytokines and their receptors.
• Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.